• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Cellebrite DI Ltd.

    3/3/26 4:59:47 PM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology
    Get the next $CLBT alert in real time by email
    S-8 1 ea0279365-s8_cellebrite.htm REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on March 3, 2026

    Registration No. 333-        

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

     

    Cellebrite DI Ltd.

    (Exact name of registrant as specified in its charter)

     

    State of Israel

     

    Not Applicable

    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)
         

    94 Shlomo Shmelzer Road
    Petah Tikva 4970602, Israel

     

    Not Applicable

    (Address of Principal Executive Offices)   (Zip Code)

     

    Cellebrite DI Ltd.
    2021 Employee Share Purchase Plan
    (Full title of the plan)

     

    Cellebrite, Inc.
    1861 International Drive

    3rd Floor

    McLean VA 22102
    (Name and address of agent for service)

     

    (800) 942-3415
    (Telephone number, including area code, of agent for service)

     

    Copies to: 

     

    Colin J. Diamond

    Shai Marshall
    Paul Hastings LLP
    200 Park Avenue
    New York, New York 10166
    Tel: (212) 318-6000

     

    Dan Shamgar

    Elad Ziv
    Meitar | Law Offices
    16 Abba Hillel Road
    Ramat Gan, 5250608, Israel
    Tel: +972 (3) 610-3100

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☒ Accelerated filer ☐
    Non-accelerated filer ☐ Smaller reporting company ☐
        Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

      

     

     

     

    EXPLANATORY NOTE

     

    Pursuant to General Instruction E of Form S-8, Cellebrite DI Ltd. (the “Registrant” or the “Company”) is filing this Registration Statement with the Securities and Exchange Commission (the “SEC”) to register 1,045,104 additional ordinary shares, par value NIS 0.00001 per share (“Ordinary Shares”), of the Registrant reserved for issuance under the Cellebrite DI Ltd. 2021 Employee Share Purchase Plan (the “ESPP”) resulting from the automatic annual increase as of January 1, 2026. This Registration Statement hereby incorporates by reference the contents of the Registrant’s Registration Statements on Form S-8 (File Nos. 333-260878 and 333-278130) filed with the SEC on November 8, 2021 and March 21, 2024, respectively, and the information required by Part II of Form S-8 is omitted, except as supplemented by the information set forth below.

     

     

     

     

    PART I
    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The information called for in Part I of Form S-8 is not being filed with or included in this Form S-8 (by incorporation by reference or otherwise) in accordance with the rules and regulations of the SEC.

     

    1 

     

     

    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The Company hereby incorporates by reference in this Registration Statement the following:

     

      ● the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2025, filed with the SEC on March 3, 2026 pursuant to Section 13(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”);

     

      ● all other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act by the Company, including the Company’s report on Form 6-K filed with the SEC on February 11, 2026; and

     

      ● the description of the Company’s Ordinary Shares contained in the Company’s Registration Statement on Form 8-A, filed with the SEC on August 30, 2021, as updated by the description of the Company’s Ordinary Shares contained in Exhibit 2.2 to the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2025, filed with the SEC on March 3, 2026, and any other amendment or report filed for the purpose of updating such description.

     

    All documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, and, to the extent specifically designated therein, reports of foreign private issuer on Form 6-K furnished by the Company to the SEC, in each case, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing or furnishing of such documents.

     

    Any statement contained herein or in a document, all or a portion of which is incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Notwithstanding the foregoing, no information is incorporated by reference in this Registration Statement where such information under applicable forms and regulations of the SEC is not deemed to be “filed” under Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, unless the report or filing containing such information indicates that the information therein is to be considered “filed” under the Exchange Act or is to be incorporated by reference in this Registration Statement.

     

    II-1 

     

     

    Item 8. Exhibits.

     

    Exhibit
    Number
      Description of Documents
    4.1   Amended and Restated Articles of Cellebrite DI Ltd. (as currently in effect) incorporated by reference to Exhibit 1.1 to the Company’s Annual Report on Form 20-F filed with the SEC on April 27, 2023.
    4.2   Specimen Ordinary Share Certificate of Cellebrite DI Ltd., incorporated by reference to Exhibit 4.5 to Amendment No. 3 to the Company’s Registration Statement on Form F-4 (File No. 333-256177), as amended, filed with the SEC on August 5, 2021.
    4.3   2021 Cellebrite DI Ltd. Employee Share Purchase Plan, incorporated by reference to Exhibit 4.7 to the Company’s Annual Report on Form 20-F filed with the SEC on March 18, 2025.
    5.1   Opinion of Meitar | Law Offices with respect to the legality of the Ordinary Shares.
    23.1   Consent of Korst Forer Gabbay & Kasierer, a member of EY Global.
    23.2   Consent of Meitar | Law Offices (included in Exhibit 5.1 to this Registration Statement).
    24.1   Power of Attorney of certain officers and directors (included on the signature page to this Registration Statement).
    107   Filing Fee Table.

     

    II-2 

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Petah Tikva, State of Israel, on the 3rd day of March, 2026.

     

      CELLEBRITE DI LTD.
       
      By: /s/ Thomas E. Hogan      
      Name: Thomas E. Hogan
      Title: Chief Executive Officer and Director

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each of the undersigned constitutes and appoints each of Thomas E. Hogan and David Barter, each acting alone, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign this Registration Statement on Form S-8 and all post-effective amendments thereto, of Cellebrite DI Ltd., and to file the same, with all exhibits thereto, and other document in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, each acting alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that any such attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

     

    Title of Capacities

     

    Date

             

    /s/ Thomas E. Hogan

      Chief Executive Officer and Director   March 3, 2026
    Thomas E. Hogan   (Principal Executive Officer)    
             

    /s/ David Barter

      Chief Financial Officer   March 3, 2026
    David Barter   (Principal Financial Officer and Principal Accounting Officer)    
             

    /s/ Adam Clammer

      Chairman   March 3, 2026
    Adam Clammer        
             

    /s/ Nadine Baudot-Trajtenberg

      Director   March 3, 2026
    Nadine Baudot-Trajtenberg        
             
    /s/ Michael D. Capellas   Director   March 3, 2026
    Michael D. Capellas        
             

    /s/ Yonatan Domnitz

      Director   March 3, 2026
    Yonatan Domnitz        
             
    /s/ Dafna Gruber   Director   March 3, 2026
    Dafna Gruber        
             

    /s/ Troy K. Richardson

      Director   March 3, 2026
    Troy K. Richardson        
             

    /s/ Ryusuke Utsumi

      Director   March 3, 2026
    Ryusuke Utsumi        
             
    /s/ Brandon Van Buren   Director   March 3, 2026
    Brandon Van Buren        

     

    II-3 

     

     

    AUTHORIZED REPRESENTATIVE

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Cellebrite DI Ltd. has signed this registration statement on March 3, 2026.

     

      CELLEBRITE, INC.
       
      By: /s/ David Barter
      Name:  David Barter
      Title: Chief Financial Officer

     

    II-4 

     

    Get the next $CLBT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLBT

    DatePrice TargetRatingAnalyst
    3/28/2024$13.00 → $13.50Buy
    Needham
    3/13/2024Mkt Perform → Outperform
    William Blair
    2/16/2024$9.00 → $12.00Neutral → Buy
    BofA Securities
    7/19/2023$11.00Buy
    Craig Hallum
    8/12/2022$6.50 → $6.00Buy → Neutral
    BofA Securities
    8/12/2022Outperform → Mkt Perform
    William Blair
    2/24/2022$10.50Overweight
    JP Morgan
    2/11/2022$10.50Buy
    Deutsche Bank
    More analyst ratings

    $CLBT
    SEC Filings

    View All

    SEC Form S-8 filed by Cellebrite DI Ltd.

    S-8 - Cellebrite DI Ltd. (0001854587) (Filer)

    3/3/26 4:59:47 PM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    SEC Form 20-F filed by Cellebrite DI Ltd.

    20-F - Cellebrite DI Ltd. (0001854587) (Filer)

    3/3/26 4:07:23 PM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    SEC Form 144 filed by Cellebrite DI Ltd.

    144 - Cellebrite DI Ltd. (0001854587) (Subject)

    2/24/26 4:31:54 PM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    $CLBT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham reiterated coverage on Cellebrite DI with a new price target

    Needham reiterated coverage of Cellebrite DI with a rating of Buy and set a new price target of $13.50 from $13.00 previously

    3/28/24 8:25:08 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    Cellebrite DI upgraded by William Blair

    William Blair upgraded Cellebrite DI from Mkt Perform to Outperform

    3/13/24 7:29:30 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    Cellebrite DI upgraded by BofA Securities with a new price target

    BofA Securities upgraded Cellebrite DI from Neutral to Buy and set a new price target of $12.00 from $9.00 previously

    2/16/24 7:23:02 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    $CLBT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cellebrite Files its 2025 Annual Report on Form 20-F

    TYSONS CORNER, Va. and PETAH TIKVA, Israel, March 4, 2026 /PRNewswire/ -- Cellebrite (NASDAQ:CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, today announced that the Company has filed its Annual Report on Form 20-F for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission (the "SEC"). Cellebrite's 2025 Annual Report on Form 20-F is available on the investor relations section of its website at https://investors.cellebrite.com/financial-information/sec-filings and on the SEC's we

    3/4/26 8:30:00 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    Cellebrite Completes Acquisition of Drone Forensics Leader SCG Canada, Inc.

    Addition of Unmanned Aerial Vehicle (UAV) forensic capabilities extends Cellebrite's AI-powered platform to one of the fastest-growing data sources in defense and public safetyTYSONS CORNER, Va. and PETAH TIKVA, Israel, March 2, 2026 /CNW/ -- Cellebrite (NASDAQ:CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, closed its acquisition of SCG Canada, Inc., a leading provider of hand-held digital forensics solutions that enable access to more than 80 of the most common UAVs. SCG's solution enables extraction, decoding and visualization of millions of data points from drones that often become key forensic artifacts.

    3/2/26 8:30:00 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    Cellebrite Announces Participation in the Morgan Stanley Technology, Media & Telecom Conference

    TYSONS CORNER, Va. and PETAH TIKVA, Israel, Feb. 24, 2026 /CNW/ -- Cellebrite (NASDAQ:CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors,  today announced the Company will participate in the upcoming Morgan Stanley Technology, Media & Telecom Conference. Relevant details include: Date:March 3, 2026Conference:Morgan Stanley Technology, Media & Telecom Conference Presentation Time:10:45 a.m. ETFormatFireside Chat Event URL:https://investors.cellebrite.com/events/event-details/morgan-stanley-technology-media-tele

    2/24/26 8:30:00 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    $CLBT
    Financials

    Live finance-specific insights

    View All

    Cellebrite Announces Record Fourth-Quarter and Full-Year 2025 Results

    Total ARR grew 21% to $480.8 million; Revenue grew 18% to $128.8 million Net income of $21.3 million supports non-GAAP net income of $36.7 million and adjusted EBITDA of $38.3 million, 29.8% adjusted EBITDA margin TYSONS CORNER, Va. and PETAH TIKVA, Israel, Feb. 11, 2026 /PRNewswire/ -- Cellebrite (NASDAQ:CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, today announced financial results for the three and twelve months ending December 31, 2025. "Cellebrite closed 2025 with a solid fourth quarter that capp

    2/11/26 7:00:00 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    Cellebrite to Report Fourth-Quarter and Fiscal Year 2025 Financial Results on February 11, 2026

    TYSONS CORNER, Va. and PETAH TIKVA, Israel, Jan. 21, 2026 /PRNewswire/ -- Cellebrite (NASDAQ:CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced it will report its fourth-quarter and fiscal year 2025 financial results before the U.S. markets open on Wednesday, February 11, 2026. Later that same morning, Cellebrite will host a live conference call and webcast to review the Company's financial results for the fourth quarter of 2025 and discuss its 2026 outlook. Relevant details include: Date: Wednesday, February 1

    1/21/26 9:00:00 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    Cellebrite Announces Third-Quarter 2025 Results

    ARR grew 19% to $439.8 million; Revenue grew 18% to $126.0 million Net income of $20.2 million supports non-GAAP net income of $36.9 million and adjusted EBITDA of $37.7 million, 29.9% adjusted EBITDA margin TYSONS CORNER, Va. and PETAH TIKVA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ:CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced financial results for the three and nine months ending September 30, 2025. "Cellebrite once again delivered a balanced and solid performance," stated Thomas E. Hogan, Cellebrite's CEO. "We exceeded the high end of our prior adjusted EBITDA guidance with revenue at the hi

    11/12/25 4:01:00 PM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    $CLBT
    Leadership Updates

    Live Leadership Updates

    View All

    Cellebrite Appoints Holly Windham as General Counsel and Chief Compliance Officer

    TYSONS CORNER, Va. and PETAH TIKVA, Israel, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Cellebrite DI Ltd (NASDAQ:CLBT), global leader in premier Digital Investigative and Intelligence solutions for the public and private sectors, today announced the appointment of Holly Windham as General Counsel and Chief Compliance Officer. Ms. Windham brings extensive legal leadership experience for growth-oriented technology companies with deep expertise spanning software, cloud platforms, cybersecurity, data privacy and public sector contracting – areas critical to Cellebrite's continued growth and market leadership. She will partner closely with Cellebrite's leadership team, overseeing all legal and complianc

    10/30/25 8:30:00 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    Cellebrite to Acquire Corellium

    TYSONS CORNER, Va. and PETAH TIKVA, Israel, June 05, 2025 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ:CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced its agreement to acquire Corellium, a leader in Arm-based virtualization software. This combination will set a new standard for digital investigations and the security of smart devices including iOS, Android, automotive systems and any Arm-based IoT device. Customers across public safety, defense, intelligence and private sectors will benefit from: Accelerated identification of mobile vulnerabilities and exploitsIndustry-first ability to visualize and interact with virtual dev

    6/5/25 7:30:00 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    Cellebrite Appoints Michael D. Capellas to Board of Directors as Lead Independent Director

    TYSONS CORNER, Va. and PETAH TIKVA, Israel, Jan. 06, 2025 (GLOBE NEWSWIRE) --  Cellebrite (NASDAQ:CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced a series of Board updates to support the Company's continued growth into 2025 and beyond. As previously detailed on November 6, 2024, Thomas E. Hogan has been appointed interim CEO to begin 2025 as part of a planned leadership transition. In conjunction with stepping into this position, Mr. Hogan remains on the Company's Board of Directors and plans to revert to his position as chairman upon the eventual appointment of a new CEO. As part of Cellebrite's ongoing commitment to

    1/6/25 8:00:00 AM ET
    $CLBT
    $CSCO
    Computer Software: Prepackaged Software
    Technology
    Computer Communications Equipment
    Telecommunications

    $CLBT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Cellebrite DI Ltd.

    SC 13D/A - Cellebrite DI Ltd. (0001854587) (Subject)

    9/17/24 4:33:52 PM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13D/A filed by Cellebrite DI Ltd.

    SC 13D/A - Cellebrite DI Ltd. (0001854587) (Subject)

    8/29/24 6:07:01 PM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G/A filed by Cellebrite DI Ltd. (Amendment)

    SC 13G/A - Cellebrite DI Ltd. (0001854587) (Subject)

    3/12/24 12:38:56 PM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology